BTIG initiated coverage of Pharma Mar (PHMMF) with a Buy rating and EUR 121 price target The current valuation is anchored by a “profitable, cash-generative commercial base” driven by Zepzelca’s established U.S. royalty stream and growing direct European sales, says the analyst, who calls EU approval and commercial launch of Zepzelca in first-line maintenance SCLC “the single largest near-term revenue inflection.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHMMF:
- PHMMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pharma Mar Secures Credit Rating Upgrade to BBB From EthiFinance
- Pharma Mar Reports Latest Transactions Under Resumed Share Liquidity Contract
- PharmaMar Wins Taiwan First-Line Maintenance Nod for Zepzelca in SCLC
- Pharma Mar Launches Employee Share Plan From Treasury Stock